Chlorhexidine

Chlorhexidine

SCHEMBL247105

CCC(=O)O.CCC(=O)O.N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SLC6A3 Q01959 2/20 0.44
CNR1 P21554 2/20 0.44
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
FOLH1 Q04609 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
EPHX1 P07099 4/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorhexidine SCHEMBL2975314 0.92 CNR1 (0.48) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL12043 0.92 CNR1 (0.48) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL247291 0.92 CNR1 (0.46) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL12044 0.92 CNR1 (0.48) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL2975320 0.92 CNR1 (0.48) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL4173718 0.92 CNR1 (0.48) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL15874034 0.91 ALDH1A1 (0.47) LMNASMN1; SMN2SLC6A3ALDH1A1POLB
Chlorhexidine SCHEMBL17967106 0.91 CNR1 (0.47) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL3192051 0.91 CNR1 (0.47) LMNASMN1; SMN2SLC6A3CNR1ALDH1A1
Chlorhexidine SCHEMBL2297671 0.91 ALDH1A1 (0.51) SMN1; SMN2SLC6A3CNR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179849-B2 Antimicrobial compositions containing colloids of oligodynamic metals C. R. BARD, INC. (US) 2007-02-20 US claimed
EP-0788305-A4 COMPOSITION FOR INACTIVATING IRRITANTS IN FLUIDS UNIV COLUMBIA (US) 1999-05-26 EP claimed
JP-H09510976-A 1997-11-04 JP claimed
EP-0788305-A1 COMPOSITION FOR INACTIVATING IRRITANTS IN FLUIDS The Trustees of Columbia University in the City of New York (US) 1997-08-13 EP claimed
WO-1995026134-A1 COMPOSITION FOR INACTIVATING IRRITANTS IN FLUIDS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1995-10-05 WO claimed
EP-4192531-A1 FORTIFIED SANITIZING COMPOSITION HAVING ANTIMICROBIAL CHARACTERISTICS 2 V Industries, Inc. (US) 2023-06-14 EP disclosed
EP-3500102-B1 ANTI-MICROBIAL COMPOSITION BYOTROL PLC (GB) 2023-06-07 EP disclosed
US-20230152311-A1 Analyte Test Strip Assays, and Test Strips and Kits for Use in Practicing the Same BECTON, DICKINSON AND COMPANY 2023-05-18 US disclosed
CN-109890955-B Antibacterial agent-resistant lactic acid bacteria AB生物有限公司 2023-05-09 CN disclosed
US-20230034034-A1 LOW-VOC CLEANING SUBSTRATES AND COMPOSITIONS THE CLOROX COMPANY 2023-02-02 US disclosed
EP-2948256-B1 ANTISEPTIC APPLICATOR CAREFUSION 2200 INC (US) 2022-12-14 EP disclosed
CN-109561694-B Antimicrobial compositions 拜奥特罗尔有限公司 2022-09-27 CN disclosed
EP-0874655-A1 TRICLOSAN-CONTAINING MEDICAL DEVICES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-11-04 EP disclosed
US-5772640-A INTRAVENOUS CATHETER; IMPREGNATING THE CATHETER IN A SOLUTION CONTAING A SOLVENT, A CHLORHEXIDINE OR DERIVATIVES OR SALTS AS ANTISEPTIC, TRICLOSAM AND BIOMEDICAL POLYMER, SOAKING TO SWELL, REMOVING AND DRYING THE TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK (US) 1998-06-30 US disclosed
US-5708023-A NONIRRITATING GEL FOR SKIN THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1998-01-13 US disclosed
US-5705532-A Triple antimicrobial composition THE TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK 1998-01-06 US disclosed
EP-0788305-A1 COMPOSITION FOR INACTIVATING IRRITANTS IN FLUIDS The Trustees of Columbia University in the City of New York (US) 1997-08-13 EP disclosed
WO-1997025085-A1 TRICLOSAN-CONTAINING MEDICAL DEVICES COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK (US) 1997-07-17 WO disclosed
WO-1997017849-A1 TRIPLE ANTIMICROBIAL COMPOSITION THE TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK (US) 1997-05-22 WO disclosed
WO-1995026134-A1 COMPOSITION FOR INACTIVATING IRRITANTS IN FLUIDS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1995-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230034034-A1 LOW-VOC CLEANING SUBSTRATES AND COMPOSITIONS SMURF1, VCL, SMURF2 LMNA 2302/4885SMN1; SMN2 2870/4885SLC6A3 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.